For years, US policymakers from both parties have worked to improve affordability of prescription drugs with little success. Insulin in particular has been a key area of focus, as insulin prices have skyrocketed over the last decade. President Biden’s Build Back Better (BBB) legislation would make significant changes across a number of key areas, but its outlook is far from clear.
Both the public and private sector have made numerous attempts to curb rising prescription drug costs with efforts ranging from policy proposals to permit Medicare to negotiate lower prices, and Express Script’s price caps for insulin co-payments.
In this webinar, a panel of top policy experts to decode the latest chatter and trends on drug pricing as we investigate the potential impact on health plan and employer benefits and spending.
Topic discussed include:
- State of the union on drug pricing initiatives, both BBB and potential for administrative action
- Strategic implications for employers and health plans
- What’s next—additional policy gaps and opportunities for diabetes reversal